In the News
Harnessing Type I CRISPR-Cas Systems for Genome Engineering in Human Cells
Using a FokI fusion design, we show that Type I CRISPR-Cas systems can be expressed, reconstituted, and faithfully trafficked to the nucleus for genome engineering in human cells.
Gene Hackers: The Young Biotech Entrepreneurs Looking to make Billions by Editing Life Itself
“When Rachel Haurwitz started her biology Ph.D. at the University of California, Berkeley, the award-winning biochemist Jennifer Doudna suggested Haurwitz investigate part of a bacterial immune system. She studied how microbes store genetic mementos of attacking viruses and recognize them to fight off future assaults. “It was an esoteric project,” Haurwitz says.”
This Scientist Turned CEO Wants to Gene-Edit a Way to Cure Cancer
In a fashionable fitted blazer, Rachel Haurwitz looks the part of a polished executive when she meets me in the largest conference room of her company, Caribou Biosciences. She’s sharp and tactical as she speaks, even though it was just a few years ago that Haurwitz traded her lab coat for a tailored suit and stepped up to lead a staff of 46 as Caribou’s CEO.
Diverse Perspectives — Insights for 2018 From Biopharma's Leading Women
When recruiting for last year’s executive outlook article, What 13 Life Science Trendsetters Expect For 2017 And Beyond, I made a concerted effort to have diversity well represented. And while we succeeded in getting a wide cross section of diverse opinions from very different organizations, I failed when it came to having female life science leaders well represented. This year Life Science Leader had 12 CEOs agree to participate (the highest number of CEOs to ever take part in this article), and five of these are women.
Meet the 30 biotech leaders under 40 who are searching for breakthrough treatments and shaping the future of medicine
Rachel Haurwitz, 32, wants to transform everything from livestock to medications using the revolutionary gene-editing technology CRISPR.